The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study
Abstract
Objective: To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee. Methods: Patients with OA of the knee were enrolled in a multicenter, double‐blind, placebo‐controlled study and randomized 2:1:2 to receive a single intraarticular injection of placebo, anakinra 50 mg, or anakinra 150 mg in their symptomatic knee. Patients were evaluated for 12 weeks postinjection. The primary end point was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to week 4. Safety assessments included the evaluation of adverse events (AEs), laboratory tests, and vital signs. Pharmacokinetic parameters were assessed in a subset of patients. Results: Of 170 patients who enrolled, 160 (94%) completed the study. The mean improvements from baseline to week 4 in the WOMAC score were not statistically different between the placebo group and the patients who received 50 mg of anakinra (P = 0.67) or 150 mg of anakinra (P = 0.77). Anakinra was well tolerated. No withdrawals due to AEs or serious AEs, and no serious infections or deaths were reported. No clinically significant trends were noted in laboratory values or vital signs. Pharmacokinetic parameters demonstrated that the mean terminal half‐life of anakinra in serum after intraarticular injection was ∼4 hours. Conclusion: Anakinra was well tolerated as a single 50‐mg or 150‐mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors
Felson, D. T., Lawrence, R. C., Dieppe, P. A., Hirsch, R., Helmick, C. G., Jordan, J. M., Kington, R. S., Lane, N. E., Nevitt, M. C., Zhang, Y., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-8-200010170-00016 · Cited by 2,519
Jordan, K. M., Arden, N. K., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Dieppe, P., Gunther, K., Hauselmann, H., Herrero-Beaumont, G., Kaklamanis, P., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011742 · Cited by 2,048
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
(2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<1905::aid-anr1>3.0.co;2-p · Cited by 1,875
The prevalence of knee osteoarthritis in the elderly. the framingham osteoarthritis study
Felson, D. T., Naimark, A., Anderson, J., Kazis, L., Castelli, W., & Meenan, R. F. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300811 · Cited by 1,621
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052771 · Cited by 1,329
Felson, D. T., & McAlindon, T. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00019 · Cited by 1,122
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
Arend, W. P., & Dayer, J. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330302 · Cited by 949
ANDERSON, J. J., & FELSON, D. T. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114939 · Cited by 892
Cited by
Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., & Carr, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60802-3 · Cited by 3,151
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)
Berenbaum, F. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.11.012 · Cited by 1,718
The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis
Sellam, J., & Berenbaum, F. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.159 · Cited by 1,500
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Synovial inflammation in osteoarthritis progression
Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E., & Guma, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00749-9 · Cited by 1,041
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis
Molnar, V., Matišić, V., Kodvanj, I., Bjelica, R., Jeleč, Ž., Hudetz, D., Rod, E., Čukelj, F., Vrdoljak, T., Vidović, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179208 · Cited by 615
Progress in intra-articular therapy
Evans, C. H., Kraus, V. B., & Setton, L. A. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.159 · Cited by 584
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Intra-articular treatment options for knee osteoarthritis
Jones, I. A., Togashi, R., Wilson, M. L., Heckmann, N., & Vangsness, C. T. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0123-4 · Cited by 525
Inflammation in joint injury and post-traumatic osteoarthritis
Lieberthal, J., Sambamurthy, N., & Scanzello, C. R. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.08.015 · Cited by 504
Current research on pharmacologic and regenerative therapies for osteoarthritis
Zhang, W., Ouyang, H., Dass, C. R., & Xu, J. (2016) · Bone Research · doi:10.1038/boneres.2015.40 · Cited by 495
Obesity, Inflammation, and Immune System in Osteoarthritis
Nedunchezhiyan, U., Varughese, I., Sun, A. R., Wu, X., Crawford, R., & Prasadam, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907750 · Cited by 466
Goldring, M. B. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12448454 · Cited by 444
Bondeson, J., Blom, A. B., Wainwright, S., Hughes, C., Caterson, B., & van den Berg, W. B. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27290 · Cited by 419
Emerging pharmaceutical therapies for osteoarthritis
Latourte, A., Kloppenburg, M., & Richette, P. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00518-6 · Cited by 418
Immunopathogenesis of osteoarthritis
Haseeb, A., & Haqqi, T. M. (2013) · Clinical Immunology · doi:10.1016/j.clim.2012.12.011 · Cited by 416
Negash, A. A., Ramos, H. J., Crochet, N., Lau, D. T. Y., Doehle, B., Papic, N., Delker, D. A., Jo, J., Bertoletti, A., Hagedorn, C. H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003330 · Cited by 414
LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis
Arra, M., Swarnkar, G., Ke, K., Otero, J. E., Ying, J., Duan, X., Maruyama, T., Rai, M. F., O’Keefe, R. J., Mbalaviele, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17242-0 · Cited by 412
Liang, Y., Xu, X., Li, X., Xiong, J., Li, B., Duan, L., Wang, D., & Xia, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c10458 · Cited by 391
Interleukin-1β signaling in osteoarthritis – chondrocytes in focus
Jenei-Lanzl, Z., Meurer, A., & Zaucke, F. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2018.10.005 · Cited by 387
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Senescent cells and osteoarthritis: a painful connection
Jeon, O. H., David, N., Campisi, J., & Elisseeff, J. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95147 · Cited by 356
Cartilage-targeting drug delivery: can electrostatic interactions help?
Bajpayee, A. G., & Grodzinsky, A. J. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.210 · Cited by 325
Novack, D. V. (2011) · Cell Research · doi:10.1038/cr.2010.159 · Cited by 315
Osteoarthritis joint pain: The cytokine connection
Miller, R. E., Miller, R. J., & Malfait, A.-M. (2014) · Cytokine · doi:10.1016/j.cyto.2014.06.019 · Cited by 314
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Recent advances in the treatment of osteoarthritis
Grässel, S., & Muschter, D. (2020) · F1000Research · doi:10.12688/f1000research.22115.1 · Cited by 307
Metabolic triggered inflammation in osteoarthritis
Wang, X., Hunter, D., Xu, J., & Ding, C. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2014.10.002 · Cited by 305
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions
Cho, Y., Jeong, S., Kim, H., Kang, D., Lee, J., Kang, S.-B., & Kim, J.-H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00710-y · Cited by 296
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
The Role of Innate Immunity in Osteoarthritis: When Our First Line of Defense Goes On the Offensive
Orlowsky, E. W., & Kraus, V. B. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.140382 · Cited by 292
Interleukin-1 function and role in rheumatic disease
Schett, G., Dayer, J.-M., & Manger, B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 279
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Cytokines as biochemical markers for knee osteoarthritis
Mabey, T. (2015) · World Journal of Orthopedics · doi:10.5312/wjo.v6.i1.95 · Cited by 263
Bjurstrom, M. F., Giron, S. E., & Griffis, C. A. (2016) · Pain Practice · doi:10.1111/papr.12252 · Cited by 62
Metadata
- Authors
- Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D., & Appleton, B. E.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2009-02-26
- Volume
- 61
- Issue
- 3
- Pages
- 344-352
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W1997957358
- Cited by
- 533
- References
- 31
- FWCI
- 17.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.